Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT02831205 Terminated - Clinical trials for Percutaneous Transluminal Coronary Angioplasty

Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease

ABSORB-LONG
Start date: July 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether ABSORB bioresorbable vascular scaffold is non-inferior to XIENCE everolimus-eluting cobalt-chromium stent with respect to target-lesion failure (TLF) at 1 year.

NCT ID: NCT02739685 Terminated - Clinical trials for Coronary Artery Disease

Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion

SCORE-CTO
Start date: September 2016
Phase: Phase 4
Study type: Interventional

The purpose of the current study is to demonstrate non-inferiority of everolimus-eluting bioresorbable vascular scaffold to everolimus-eluting stents in patients with chronic total occlusion regarding the antirestenotic efficacy at 8 to 10-month angiographic follow-up.

NCT ID: NCT02694016 Terminated - Myocardial Ischemia Clinical Trials

Remote Ischemic Preconditioning in Patients Undergoing Isolated Aortic Valve Replacement Surgery

Start date: February 2016
Phase: N/A
Study type: Interventional

The goal is to investigate the efficacy, safety and possible neuro- and cardioprotective effects of remote ischemic preconditioning (RIPC) in adult cardiac patients undergoing isolated aortic valve replacement surgery with a biological prosthesis. Neuropsychological evaluation preoperatively and at 30d after surgery will establish if there are any differences in neuropsychological performance between groups. A large array of biochemical markers will be analyzed from plasma samples taken at different time points. Additionally skin biopsies from the lower limb will be taken before and after performing RIPC on said limb. During the venous cannulation phase a atrial biopsy will be taken. The biochemical markers from plasma and tissue samples will be used to asses brain tissue damage, inflammation and cardiac tissue damage between groups. This will be a single center prospective randomized study with two groups. A intervention group (RIPC) and a control group. Study size is: 40 patients in total, 20 patients per group.

NCT ID: NCT02632292 Terminated - Clinical trials for Coronary Artery Disease

EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus

SUGAR-EVE
Start date: January 2016
Phase: Phase 4
Study type: Interventional

Prospective, randomized, controlled, multicenter, open-label study to compare everolimus-eluting bioresorbable vascular scaffolds to everolimus-eluting stents in patients with diabetes mellitus.

NCT ID: NCT02601664 Terminated - Clinical trials for Coronary Artery Disease

Randomized-controlled Trial of a Combined vs. Conventional Percutaneous Intervention for Near-Infrared Spectroscopy Defined High-Risk Native Coronary Artery Lesions

CONCERTO
Start date: November 2015
Phase: Phase 4
Study type: Interventional

Design: Single center, single-blind randomized controlled trial of patients with high risk native coronary artery lesions (defined as ≥2 contiguous yellow blocks on the block chemogram) requiring clinically indicated percutaneous coronary intervention. Patients will be randomized to either a combined intervention or conventional PCI. Cardiac biomarker measurements will be performed before PCI and 18-24 hours later. Treatment: Combined intervention consisting of pre-PCI intracoronary vasodilator and glycoprotein IIb/IIIa inhibitor administration, use of an EPD if technically feasible, and complete coverage of the lipid core plaque, if technically feasible. Control: Conventional PCI. Duration: 30 days follow-up. The primary trial objective is to compare the incidence and size of periprocedural MI, as assessed by the peak post-PCI troponin distribution in the two study groups. The secondary endpoints are: (1) Reduction in the incidence of >3x and >10x upper limit of normal increase in CK-MB. (2) Reduction in the incidence of slow flow/no-reflow post PCI. (3) Lower incidence of major adverse cardiac events, defined as the composite of death, acute coronary syndrome, or coronary revascularization) during 30-day follow-up.

NCT ID: NCT02543632 Terminated - Heart Failure Clinical Trials

PARACHUTE V PercutAneous Ventricular RestorAtion in Chronic Heart FailUre Due to Ischemic HearT DiseasE.

P5
Start date: August 2015
Phase: N/A
Study type: Observational [Patient Registry]

Prospective, multi-center, post-market, non-randomized, nested-control, observational study of the CE marked CardioKinetix Parachute Implant System.

NCT ID: NCT02494284 Terminated - Clinical trials for Coronary Artery Disease

Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

STAMP-DES
Start date: December 22, 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare short-term (6-month Dual Anti Platelet Therapy(DAPT) followed by clopidogrel monotherapy) vs. standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy) on clinically relevant bleeding complications (Bleeding Academic Research Consortium(BARC) type 2, 3, or 5)31 in patients after zotarolimus-eluting stent implantation.

NCT ID: NCT02474485 Terminated - Clinical trials for Coronary Artery Disease

Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR

AbsorbISR
Start date: March 2015
Phase: N/A
Study type: Interventional

AbsorbISR is a randomized, controlled trial, single center, prospective, not blinded to evaluate two strategies of in stent restenosis treatment: Implantation of drug eluting bioresorbable stent scaffold Absorb® vs. balloon angioplasty with drug eluting balloon Sequent Please®.

NCT ID: NCT02463110 Terminated - Depression Clinical Trials

Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin

ANDROS
Start date: July 2015
Phase: Phase 4
Study type: Interventional

Primary purpose: To evaluate the evolution in time of the antiaggregant platelet effect of sertraline (SSRI) compared to placebo in depressive patients with ACS (Acute Coronary Syndrome) and treated as recommended by a double antiplatelet therapy, aspirin and clopidogrel. Hypothesis: The benefits of SSRIs observed in depressive patients with ACS are related to an antiplatelet effect.

NCT ID: NCT02440646 Terminated - Clinical trials for Coronary Artery Disease

Natural History of Atherosclerosis in Real-World Patients Underwent Computed Tomography Angiography

REALITY
Start date: May 2015
Phase: N/A
Study type: Observational [Patient Registry]

In a prospective cohort single-center observational study, 720-1080 chest pain patients ('all-comers' REALITY registry of CTA patients, Ural Institute of Cardiology, Yekaterinburg, Russia; www.cardio-burg.ru) with or without acute coronary syndrome will be enrolled who admitted to the chest pain outpatient center (The Heart Clinics, Yekaterinburg, Russia; www.hclinic.ru) between September 2010 and May 2015 underwent functional testing and computed tomography angiography, and/ or 3D quantitative coronary angiography with or without further percutaneous coronary intervention. Subsequent plaque burden/ % stenosis (adjusted with technical limitations of CTA and 3D QCA), major adverse cardiovascular events (death from cardiac causes, cardiac arrest, myocardial infarction, or rehospitalization due to unstable or progressive angina) will be judged to be related to either originally treated (culprit) lesions or untreated (non-culprit) lesions. Moreover, the clinical potential of CTA vs 3D QCA in two real-world patient flows of the Chest Pain center will be estimated with the special focus on safety (contrast-induced nephropathy, radiocontrast-induced thyroid dysfunction, and radiation dose). The diagnostic accuracy of both CTA and 3D QCA will be analyzed in deceased patients. The follow-up period will achieve 3-5 years when retro- and prospectively collected clinical events and imaging outcomes will be determined at the hospital, in 1, 6, 12, 24, 36, 48 and 60 months after the first imaging examination. The independent ethics expertise will be provided by the Ural Medical University, Yekaterinburg, Russia (www.usma.ru). The monitoring of the clinical data with imaging as well as further CoreLab expertise (software of Medis) will be provided by De Haar Research Foundation, Rotterdam, the Netherlands.